3D-Printed Capsaicin-Loaded Injectable Implants for Targeted Delivery in Obese Patients

• Published in: AAPS PharmSciTech 2023-10, Vol.24 (7), p.200-200, Article 200
• Main Authors: Annaji, Manjusha, Mita, Nur, Heard, Jessica, Kang, Xuejia, Poudel, Ishwor, Fasina, Oladiran, Baskaran, Padmamalini, Boddu, Sai H. S., Tiwari, Amit K., Chen, Pengyu, Lyman, Candace C., Babu, R. Jayachandra
• Format: Article
• Language: English
• Subjects: Additive Manufacturing and Artificial Intelligence/Machine Learning; Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Pharmacology/Toxicology; Pharmacy; Research Article
• ISSN: 1530-9932; 1530-9932
• DOI: 10.1208/s12249-023-02647-z

Diet-induced obesity and hyperlipidemia are a growing public health concern leading to various metabolic disorders. Capsaicin, a major bioactive compound obtained from natural chili peppers, has demonstrated its numerous beneficial roles in treating obesity and weight loss. Current treatment involves either administration of antiobesity drugs or surgical procedures such as Roux-en-Y-gastric bypass or sleeve gastrectomy, both of which are associated with serious side effects and poor patient acceptance. Capsaicin, a pungent molecule, has low oral bioavailability. Therefore, there is a need for the development of site-specific drug delivery system for capsaicin. The present study is aimed at preparing and characterizing 3D-printed capsaicin-loaded rod-shaped implants by thermoplastic extrusion-based 3D printing technology. The implants were printed with capsaicin-loaded into a biodegradable polymer, polycaprolactone, at different drug loadings and infill densities. The surface morphology revealed a smooth and uniform external surface without any capsaicin crystals. DSC thermograms showed no significant changes/exothermic events among the blends suggesting no drug polymer interactions. The in vitro release studies showed a biphasic release profile for capsaicin, and the release was sustained for more than three months (~ 85% released) irrespective of drug loading and infill densities. The HPLC method was stability-indicating and showed good resolution for its analogs, dihydrocapsaicin and nordihydrocapsaicin. The implants were stable for three months at accelerated conditions (40°C) without any significant decrease in the assay of capsaicin. Therefore, capsaicin-loaded implants can serve as a long-acting injectable formulation for targeting the adipose tissue region in obese patients. Graphical Abstract